All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the Lymphoma Hub was pleased to speak to Constantine Tam, Peter MacCallum Cancer Centre, Melbourne, AU. We asked, What predicts disease progression on venetoclax?
What predicts disease progression on venetoclax?
Tam begins by discussing the clinical and genetic factors that predispose a patient to progressing on venetoclax. These include traditional risk factors for chronic lymphocytic leukemia and P53 dysfunction, covered in studies such as CLL14 and MURANO. Finally, he discusses the mechanisms of resistance to venetoclax, describing how many patients who develop resistance have a spectrum of Bcl-2 mutations.
Venclexta plus Rituxan approved by FDA for previously treated CLL
Venclexta plus rituxan approved by FDA for previously treated CLL
4-year results from the phase III MURANO study
Summary of the data from a 4-year follow-up of the phase III MURANO study investigating the efficacy and safety of venetoclax plus rituximab compared with bendamustine plus rituximab in patients with R/R...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox